336 related articles for article (PubMed ID: 20233288)
21. An Asian multinational prospective observational registry of patients with benign prostatic hyperplasia, with a focus on comorbidities, lower urinary tract symptoms and sexual function.
Li MK; Garcia L; Patron N; Moh LC; Sundram M; Leungwattanakij S; Pripatnanont C; Cheng C; Chi-Wai M; Loi-Cheong N
BJU Int; 2008 Jan; 101(2):197-202. PubMed ID: 18005205
[TBL] [Abstract][Full Text] [Related]
22. Tadalafil 2.5 or 5 mg administered once daily for 12 weeks in men with both erectile dysfunction and signs and symptoms of benign prostatic hyperplasia: results of a randomized, placebo-controlled, double-blind study.
Egerdie RB; Auerbach S; Roehrborn CG; Costa P; Garza MS; Esler AL; Wong DG; Secrest RJ
J Sex Med; 2012 Jan; 9(1):271-81. PubMed ID: 21981682
[TBL] [Abstract][Full Text] [Related]
23. An open, non-comparative, multicentre study on the impact of alfuzosin on sexual function using the Male Sexual Health Questionnaire in patients with benign prostate hyperplasia.
Kim MK; Cheon J; Lee KS; Chung MK; Lee JY; Lee SW; Kim SW; Chung BH; Park K; Park JK
Int J Clin Pract; 2010 Feb; 64(3):345-50. PubMed ID: 19891715
[TBL] [Abstract][Full Text] [Related]
24. Tamsulosin 0.4 mg once daily: effect on sexual function in patients with lower urinary tract symptoms suggestive of benign prostatic obstruction.
Höfner K; Claes H; De Reijke TM; Folkestad B; Speakman MJ
Eur Urol; 1999 Oct; 36(4):335-41. PubMed ID: 10473995
[TBL] [Abstract][Full Text] [Related]
25. Efficacy and safety of combined oral therapy with tadalafil and alfuzosin: an integrated approach to the management of patients with lower urinary tract symptoms and erectile dysfunction. Preliminary report.
Liguori G; Trombetta C; De Giorgi G; Pomara G; Maio G; Vecchio D; Ocello G; Ollandini G; Bucci S; Belgrano E
J Sex Med; 2009 Feb; 6(2):544-52. PubMed ID: 19138360
[TBL] [Abstract][Full Text] [Related]
26. Tadalafil - a therapeutic option in the management of BPH-LUTS.
Carson CC; Rosenberg M; Kissel J; Wong DG
Int J Clin Pract; 2014 Jan; 68(1):94-103. PubMed ID: 24341303
[TBL] [Abstract][Full Text] [Related]
27. Correlation between Lower Urinary Tract Symptoms (LUTS) and sexual function in benign prostatic hyperplasia: impact of treatment of LUTS on sexual function.
Jung JH; Jae SU; Kam SC; Hyun JS
J Sex Med; 2009 Aug; 6(8):2299-304. PubMed ID: 19493292
[TBL] [Abstract][Full Text] [Related]
28. Safety and efficacy of a prolonged-release formulation of alfuzosin 10 mg once daily in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia.
Kongkanand A; Chodchoy V; Lojanapiwat B; Pumpaisanchai S; Ratana-Olarn K; Sae-Tang P; Taweemonkongsap T
J Med Assoc Thai; 2009 Jul; 92(7):969-78. PubMed ID: 19626818
[TBL] [Abstract][Full Text] [Related]
29. Prospective study of men with clinical benign prostatic hyperplasia treated with alfuzosin by general practitioners: 1-year results.
Lukacs B; Leplège A; Thibault P; Jardin A
Urology; 1996 Nov; 48(5):731-40. PubMed ID: 8911517
[TBL] [Abstract][Full Text] [Related]
30. Effect of tamsulosin hydrochloride on lower urinary tract symptoms and quality of life in patients with benign prostatic hyperplasia. Evaluation using bother score.
Yoshida M; Sugiyama Y; Masunaga K; Maeda Y; Satoji Y; Nagata T; Inadome A
Drugs Today (Barc); 2007 Jun; 43 Suppl B():1-7. PubMed ID: 17612712
[TBL] [Abstract][Full Text] [Related]
31. Effectiveness of tadalafil 5 mg once daily in the treatment of men with lower urinary tract symptoms suggestive to benign prostatic hyperplasia with or without erectile dysfunction: results from naturalistic observational TadaLutsEd study.
Bechara A; Casabe A; Rodriguez Baigorri G; Cobreros C
J Sex Med; 2014 Feb; 11(2):498-505. PubMed ID: 24224728
[TBL] [Abstract][Full Text] [Related]
32. Treatment of lower urinary tract symptoms suggestive of benign prostatic hyperplasia: sexual function.
Lowe FC
BJU Int; 2005 Jun; 95 Suppl 4():12-8. PubMed ID: 15871731
[TBL] [Abstract][Full Text] [Related]
33. The impact of the bladder wall thickness on the outcome of the medical treatment using alpha-blocker of BPH patients with LUTS.
Salah Azab S; Elsheikh MG
Aging Male; 2015 Jun; 18(2):89-92. PubMed ID: 25295872
[TBL] [Abstract][Full Text] [Related]
34. Erectile dysfunction and lower urinary tract symptoms associated with benign prostatic hyperplasia (LUTS/BPH) combined responders to tadalafil after 12 weeks of treatment.
Roehrborn CG; Egan KB; Miner MM; Ni X; Wong DG; Rosen RC
BJU Int; 2016 Jul; 118(1):153-60. PubMed ID: 26765325
[TBL] [Abstract][Full Text] [Related]
35. Monotherapy with tadalafil or tamsulosin similarly improved lower urinary tract symptoms suggestive of benign prostatic hyperplasia in an international, randomised, parallel, placebo-controlled clinical trial.
Oelke M; Giuliano F; Mirone V; Xu L; Cox D; Viktrup L
Eur Urol; 2012 May; 61(5):917-25. PubMed ID: 22297243
[TBL] [Abstract][Full Text] [Related]
36. Preservation of Sexual Function 5 Years After Water Vapor Thermal Therapy for Benign Prostatic Hyperplasia.
McVary KT; El-Arabi A; Roehrborn C
Sex Med; 2021 Dec; 9(6):100454. PubMed ID: 34731779
[TBL] [Abstract][Full Text] [Related]
37. Multicenter, prospective, comparative cohort study evaluating the efficacy and safety of alfuzosin 10 mg with regard to blood pressure in men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia with or without antihypertensive medications.
Zhang LT; Lee SW; Park K; Chung WS; Kim SW; Hyun JS; Moon DG; Yang SK; Ryu JK; Yang DY; Moon KH; Min KS; Park JK
Clin Interv Aging; 2015; 10():277-86. PubMed ID: 25653511
[TBL] [Abstract][Full Text] [Related]
38. A randomised, placebo-controlled study to assess the efficacy of twice-daily vardenafil in the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia.
Stief CG; Porst H; Neuser D; Beneke M; Ulbrich E
Eur Urol; 2008 Jun; 53(6):1236-44. PubMed ID: 18281145
[TBL] [Abstract][Full Text] [Related]
39. Preservation of sexual function with the prostatic urethral lift: a novel treatment for lower urinary tract symptoms secondary to benign prostatic hyperplasia.
Woo HH; Bolton DM; Laborde E; Jack G; Chin PT; Rashid P; Thavaseelan J; McVary KT
J Sex Med; 2012 Feb; 9(2):568-75. PubMed ID: 22172161
[TBL] [Abstract][Full Text] [Related]
40. Development and validation of four-item version of Male Sexual Health Questionnaire to assess ejaculatory dysfunction.
Rosen RC; Catania JA; Althof SE; Pollack LM; O'Leary M; Seftel AD; Coon DW
Urology; 2007 May; 69(5):805-9. PubMed ID: 17482908
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
